Pfizer (PFE) Bets Big on RSV and Cancer Care

Pfizer (PFE) is enforcing a Belgian court judgment against Poland and Romania for unpaid COVID-19 vaccine orders, targeting air traffic control fees. The court ordered the countries to pay $2.1 billion for declined vaccine doses. Pfizer's Q2 results beat expectations, with Eliquis sales up 21% and Padcev up 23%. The company raised its 2026 revenue outlook to $60.5B-$62.5B. Legal risks and reputational concerns remain.

Pfizer will pay $44M to settle a class action lawsuit alleging it misrepresented Chantix's safety before a recall due to contamination. The settlement covers U.S. retail purchases from 2015 to 2021. Chantix, approved in 2006, is a smoking-cessation drug.

Pfizer (PFE) and BioNTech (BNTX) received FDA approval for their updated COVID-19 vaccine, COMIRNATY XFG, targeting the XFG variant. The approval secures their position in seasonal COVID-19 immunizations, providing a stable revenue stream. For Pfizer, this supports cash flow and pipeline investments, while for BioNTech, it validates its mRNA platform and maintains market share. Both companies face risks from potential demand declines and market contraction.

Apple led The Irish Times' Top 1,000 rankings with €209.3bn revenue and €72bn profit. Microsoft, Meta, and Google followed. Eli Lilly entered the top 10. CRH was the largest indigenous company. Apple and Meta reduced Irish headcounts. Irish corporation taxes surged due to tech profits.

The FDA is scrutinizing REGENXBIO's RGX-202 and Solid Biosciences' SGT-003, both Duchenne muscular dystrophy treatments, for accelerated approval. The FDA requires evidence that microdystrophin expression predicts clinical benefit, citing Pfizer's failed CIFFREO trial as a cautionary example. REGENXBIO reported 93% of patients reached 10% microdystrophin expression, but functional data is limited. The FDA seeks robust evidence before approval, given the permanent nature of gene therapy.

Karnataka FDA revoked 16 pharmacy licenses, suspended 8, and Pfizer's distribution center license amid a counterfeit drug probe. Fake drugs worth ₹5.05 crore were seized. Pfizer stated it is cooperating with authorities, prioritizing patient safety and product quality.